Kymera Therapeutics, Inc. (KYMR) shares ended the last trading session 13.8% higher at $23.95. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 36.7% loss over the past four weeks.
Shares rallied due to broader market optimism following President Trump's tweet that there would be a 90-day pause on reciprocal tariffs for non-retaliating countries. Kymera also announced the appointment of Noah Goodman as its new Chief Business Officer.
This company is expected to post quarterly loss of $0.93 per share in its upcoming report, which represents a year-over-year change of -34.8%. Revenues are expected to be $9.88 million, down 4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Kymera Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KYMR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Kymera Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, BioHarvest Sciences Inc. (BHST), finished the last trading session 2.9% higher at $5.40. BHST has returned 1.6% over the past month.
BioHarvest Sciences Inc.'s consensus EPS estimate for the upcoming report has changed -66.7% over the past month to -$0.16. Compared to the company's year-ago EPS, this represents a change of +54.3%. BioHarvest Sciences Inc. currently boasts a Zacks Rank of #4 (Sell).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kymera Therapeutics, Inc. (KYMR) : Free Stock Analysis Report
BioHarvest Sciences Inc. (BHST) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.